J. Freddo

发表

Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.

Patrick F. Smith, Navita L. Mallalieu, M. Rahimy, 2014, Clinical therapeutics.

Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin.

S. Kirmani, S. Yen, D. Shalinsky, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

448PDRXDX-101, AN ORAL PAN-TRK, ROS1, AND ALK INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS WITH RELEVANT MOLECULAR ALTERATIONS.

P. David Pearson, A. Isacchi, G. Pelosi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

32P following negative second-look laparotomy for epithelial ovarian cancer.

B. Qaqish, M. Varia, L. Rogers, 1993, Gynecologic oncology.

Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.

P. David Pearson, G. Pelosi, M. Martignoni, 2014 .

Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer.

S. Howell, S. Kirmani, P. Braly, 1993, Obstetrics and gynecology.

2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

T. Hassanein, J. McHutchison, E. Lawitz, 2010 .

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

R. Herbst, H. Rugo, G. Wilding, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

R. Motzer, M. Michaelson, G. Wilding, 2007, The Lancet. Oncology.

Cytoreductive surgery in advanced epithelial cancer of the ovary: The impact of aortic and pelvic lymphadenectomy

G. Gross, N. Spirtos, S. Ballon, 1995, Gynecologic oncology.

Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors.

D. McNeel, G. Daniels, A. Mita, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7

R. D. de Knegt, A. Boonstra, H. Janssen, 2012, Antiviral therapy.

Randomised clinical trial: anti‐viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV

R. D. de Knegt, A. Boonstra, H. Janssen, 2011, Alimentary pharmacology & therapeutics.

Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients

B. Walker, S. Akira, J. Kaldor, 2011 .

Randomisedclinicaltrial:anti-viralactivityofANA773,anoral inducerofendogenousinterferonsactingviaTLR7,inchronicHCV

A. Boonstra, H. Janssen, S. Fletcher, 2011 .

An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer.

N. Agarwal, J. Infante, D. Rathkopf, 2019, Journal of Clinical Oncology.

An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC).

N. Agarwal, D. Rathkopf, L. Rosen, 2018 .

1055 ANTIVIRAL ACTIVITY OF ANA598, A POTENT NON- NUCLEOSIDE POLYMERASE INHIBITOR, IN CHRONIC HEPATITIS C PATIENTS

E. Lawitz, E. Godofsky, M. Rahimy, 2009 .

Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

C. Theuer, A. Trigeiro, F. Robert, 2021 .

Phase I trial of cisplatin in combination with glutathione.

S. Howell, S. Kirmani, P. Braly, 1994, Gynecologic oncology.

Phase I and pharmacokinetic study of intraperitoneal topotecan

Stephen B. Howell, S. Howell, P. Braly, 2004, Investigational New Drugs.

Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7

R. D. de Knegt, A. Boonstra, H. Janssen, 2012, Antiviral therapy.